Corestemchemon Inc
166480
Company Profile
Business description
Corestemchemon Inc is a biopharmaceutical company that researches and commercializes stem cell technology. It has developed NEURONATA-R inj., a stem cell therapy for Lou Gehrig's disease which is a rare incurable disease, for the first ALS treatment. Its stem cell therapeutics for Lou Gehrig's disease have a pipeline of incurable diseases such as lupus, multiple system atrophy, and osteoarthritis, and plans to preoccupy the market by focusing on developing therapies for rare incurable diseases based on a development success reference of stem cell therapy for the Lou Gehrig's disease.
Contact
Pangyo 255 beongil 24 I & C Building, 2nd Floor
yeonggi-do, Bundang-gu
Seongnam
Seoul13486
KORT: +82 24973711
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
371
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,959.70 | 106.00 | 1.35% |
| CAC 40 | 7,273.12 | 168.32 | 2.37% |
| DAX 40 | 20,954.83 | 580.73 | 2.85% |
| Dow JONES (US) | 40,641.68 | 428.97 | 1.07% |
| FTSE 100 | 8,134.34 | 170.16 | 2.14% |
| HKSE | 21,417.40 | 502.71 | 2.40% |
| NASDAQ | 16,899.64 | 175.19 | 1.05% |
| Nikkei 225 | 33,982.36 | 396.78 | 1.18% |
| NZX 50 Index | 12,107.54 | 88.41 | 0.74% |
| S&P 500 | 5,425.89 | 62.53 | 1.17% |
| S&P/ASX 200 | 7,748.60 | 102.10 | 1.34% |
| SSE Composite Index | 3,262.81 | 24.58 | 0.76% |